Using Growth Hormone to Treat Gastroparesis
Official title: Low-dose Growth Hormone for the Treatment of Gastroparesis
Run by Mayo Clinic · NCT06803589 · Data updated 2026-11-12
This study is testing if Growth Hormone can help people with gastroparesis feel better when other treatments haven't worked.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 2 sites (Phoenix, Arizona and 1 other locations) |
| Status | Recruiting |
| Started | October 22, 2024 |
| Main results expected | October 2027 |
| Study ends | December 2027 |
| Registry record updated | April 16, 2026 |
| Trial ID | NCT06803589 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals with gastroparesis symptoms lasting over six months that have not responded to standard treatments.
✕Probably not a fit
Patients with a history of growth hormone deficiency, diabetes, or other specified exclusion criteria may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of Growth Hormone in alleviating symptoms in patients suffering from gastroparesis, a condition characterized by delayed gastric emptying. Participants will be selected based on their chronic symptoms that have not improved with standard treatments, and their symptom severity will be assessed using the Gastroparesis Cardinal Symptom Index. The study is designed as an early-phase interventional trial to gather preliminary data on the potential benefits of this treatment approach.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life for patients with gastroparesis by alleviating their symptoms.
How similar studies have gone: While this approach is novel, similar studies exploring hormonal treatments for gastrointestinal disorders have shown promise, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Symptoms \> 6 months that have not responded satisfactorily to standard treatment. * For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of \>21 Exclusion Criteria: * Known history of GH deficiency, hypothalamic or pituitary disease * Diabetes * Prior use of GH therapy * Age-adjusted low serum IGF1 * Women on oral estrogen therapy6 * Pregnancy or nursing * History of malignant solid tumors * Obesity (BMI \> 30)History of coronary and thromboembolic diseases. * History of sarcoidosis * History of pituitary surgery * History of thyroid nodules. * Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study. * Failure to give informed consent.
Where it's running
-
Mayo Clinic
Phoenix, Arizona, United States Recruiting -
Mayo Clinic in Arizona
Scottsdale, Arizona, United States Recruiting
Study contacts
- Principal investigator: Tisha Lunsford — Mayo Clinic
- Study coordinator: Guillermo GI Program Coordinator, Research
- Email: barahona.guillermo@mayo.edu
- Phone: 480-301-4679
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Gastric-focused ultrasound to see if it changes stomach activity and symptoms
This study tests whether noninvasive stomach-focused ultrasound can alter post-meal stomach electrical activity and symptoms in adults with gastroparesis or delayed gastric emptying, using a sham control in a crossover design.
-
Gastric emptying and feeding tolerance in ICU patients by vasopressor dose
This study tests whether vasopressor dose affects how well stomach contents empty during tube feeding in critically ill patients.
-
Virtual poetry workshops to boost well-being for people with digestive symptoms
This study tests whether participating in online poetry workshops can improve emotional well-being for adults with chronic digestive symptoms and anxiety or depression.
-
Risk prediction for gastric retention during sedated gastroscopy
This study will test a simple grading system and prediction model to see if clinicians can identify which adults are likely to have significant stomach contents before sedated gastroscopy.
-
Prokinetics and Body Surface Gastric Mapping in Dyspeptic Patients
This study tests whether using Body Surface Gastric Mapping can help predict which medications will help people with gastroparesis or functional dyspepsia see improvement.
-
Implanting a gastric pacemaker to treat gastroparesis
This study is testing whether a gastric pacemaker can help people with severe gastroparesis who haven't found relief from other treatments by improving their stomach function and reducing symptoms like nausea and bloating.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.